Cencora
0HF3.L
$337.94 0.27%
Exchange: LSE | Sector: Healthcare | Industry: Medical Distribution
Q3 2025
Published: Aug 6, 2025

Earnings Highlights

  • Revenue of $80.66B up 8.7% year-over-year
  • EPS of $3.52 increased by 45.5% from previous year
  • Gross margin of 3.6%
  • Net income of 687.40M
  • ""We are investing heavily in our logistics capabilities and technologies to streamline our distribution channels and enhance service delivery to our clients."" - CEO
0HF3.L
Cencora

Executive Summary

In Q3 2025, Cencora (0HF3.L) reported a strong revenue of $80.66 billion, reflecting an 8.65% year-over-year growth. Despite facing pressures in gross profit margins, the firm managed to deliver net income of $687.4 million, a 42.18% increase YoY, indicating solid operational execution amidst challenging market conditions. Management highlighted their commitment to optimizing operational efficiencies and expanding their market share in both domestic and international markets, anticipating that their business positioning will yield favorable outcomes moving into the next quarters.

Notably, the company maintained a strong liquid position with $2.23 billion in cash, though operational cash flow turned negative primarily due to working capital adjustments. Investor confidence is buoyed by Cencora's strategic investments in technology and clinical services that enable comprehensive healthcare solutions aligned with market demands.

Key Performance Indicators

Revenue
Increasing
80.66B
QoQ: 6.90% | YoY: 8.65%
Gross Profit
Increasing
2.91B
3.60% margin
QoQ: -4.99% | YoY: 39.32%
Operating Income
Increasing
867.65M
QoQ: -16.26% | YoY: 23.36%
Net Income
Increasing
687.40M
QoQ: -4.24% | YoY: 42.18%
EPS
Increasing
3.55
QoQ: -4.05% | YoY: 45.49%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 80,663.53 3.52 +8.7% View
Q2 2025 75,453.67 3.68 +10.3% View
Q1 2025 81,487.06 2.50 +12.8% View
Q4 2024 79,050.11 0.02 +14.7% View
Q3 2024 74,241.35 2.42 +7.7% View